Universe Pharmaceuticals INC (NASDAQ:UPC) Sees Large Decline in Short Interest

Universe Pharmaceuticals INC (NASDAQ:UPC) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 6,382 shares, a decrease of 58.7% from the July 15th total of 15,446 shares. Based on an average trading volume of 1,046,971 shares, the short-interest ratio is currently 0.0 days. Currently, 0.3% of the shares of the stock are short sold.

Universe Pharmaceuticals Stock Performance

Universe Pharmaceuticals stock traded down $0.22 during midday trading on Friday, reaching $5.65. The company’s stock had a trading volume of 32,365 shares, compared to its average volume of 2,100,680. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.90 and a current ratio of 4.05. Universe Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $17.96. The business has a 50-day moving average price of $4.66 and a 200-day moving average price of $3.60.

Universe Pharmaceuticals (NASDAQ:UPC) last posted its earnings results on Wednesday, July 29th. The company reported ($1.38) EPS for the quarter. The firm had revenue of $4.52 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Universe Pharmaceuticals currently has an average rating of “Sell”.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.